Clarus Ventures’s ESSA Pharma EPIX Stock Holding History

Clarus Ventures’s Portfolio EPIX Stock Details EPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$5.01M	Hold	1,668,560	–	–	1.18%	9
2018 Q2	$6.32M	Sell	1,668,560 -1	-0%	-$4	2.25%	7
2018 Q1	$6.37M	Buy	1,668,561 +1,562,500	+1,473%	+$6.51M	6.52%	5
2017 Q4	$464K	Hold	106,061	–	–	0.46%	6
2017 Q3	$615K	Hold	106,061	–	–	0.5%	5
2017 Q2	$1.17M	Hold	106,061	–	–	1.07%	5
2017 Q1	$6.62M	Hold	106,061	–	–	4.93%	5
2016 Q4	$4.64M	Hold	106,061	–	–	3.06%	6
2016 Q3	$5.83M	Hold	106,061	–	–	3.58%	6
2016 Q2	$6.26M	Hold	106,061	–	–	5.47%	6
2016 Q1	$6.89M	Buy	+106,061	New	+$6.92M	5.18%	6

Other funds holding EPIX

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $62.3B AUM 44.64% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Clarus Ventures's EPIX Position: Q3 2018 in Review

Clarus Ventures held its ESSA Pharma (EPIX) position steady in Q3 2018 at 1,668,560 shares worth $5.01M. The position accounts for 1.18% of the portfolio, ranked #9.

Clarus Ventures first reported a position in EPIX in Q1 2016 and has held it in 11 quarters since. The position peaked at $6.89M in Q1 2016. 8 funds tracked by Wall St. Rank hold EPIX as of Q3 2018.

Clarus Ventures held 1,668,560 shares of ESSA Pharma worth $5.01M as of Q3 2018.
Clarus Ventures left its ESSA Pharma share count unchanged in Q3 2018.
ESSA Pharma made up 1.18% of Clarus Ventures's portfolio in Q3 2018, its #9 holding.
Clarus Ventures first reported a position in ESSA Pharma in Q1 2016 and has held it in 11 quarters since.
Clarus Ventures's ESSA Pharma position peaked at $6.89M in Q1 2016.
8 funds tracked by Wall St. Rank held ESSA Pharma as of Q3 2018.

Based on Clarus Ventures's 13F filing for Q3 2018, filed 14 Nov 2018.